[The syndrome of growth hormone deficiency in adults: current criteria for the diagnosis and treatment] (Q73878818)

growth hormone deficiency

7 November 2019

main subject

1 reference

J J Díez

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10846703%20AND%20SRC:MED&resulttype=core&format=json

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10846703%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

publication date

1 April 2000

1 reference

7 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10846703%20AND%20SRC:MED&resulttype=core&format=json

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10846703%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

volume

114

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10846703%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

page(s)

468-477

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10846703%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

issue

12

1 reference

The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency

7 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Beneficial effects of growth hormone treatment in GH-deficient adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Recombinant human growth hormone: old and novel uses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Clinical applications of recombinant human growth hormone in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Premature mortality due to cardiovascular disease in hypopituitarism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

The growth hormone deficiency syndrome in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Psychological well-being before and after growth hormone treatment in adults with growth hormone deficiency.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Decreased psychological well-being in adult patients with growth hormone deficiency.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Impaired social status of growth hormone deficient adults as compared to controls with short or normal stature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

The development, reliability and validity of a disease specific quality of life model for adults with growth hormone deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Quality of life, body composition and muscle strength in adult growth hormone deficiency: the influence of growth hormone replacement therapy for up to 3 years.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

One-year follow-up of quality of life in adults with untreated growth hormone deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

The QoL-AGHDA: an instrument for the assessment of quality of life in adults with growth hormone deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Growth hormone treatment of adults with growth hormone deficiency: results of a 13-month placebo controlled cross-over study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as on body composition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Comparison of measures of body composition in a trial of low dose growth hormone replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Body composition in adult growth hormone-deficient men, assessed by anthropometry and bioimpedance analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Cardiovascular risk factors in adult patients with growth hormone deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Abnormal body composition and reduced bone mass in growth hormone deficient hypopituitary adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Growth Hormone Deficiency in Adulthood and the Effects of Growth Hormone Replacement: A Review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Reduced bone mineral content in adult patients with growth hormone deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Serum lipid levels in growth hormone-deficient men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

High incidence of cardiovascular disease and increased prevalence of cardiovascular risk factors in women with hypopituitarism not receiving growth hormone treatment: preliminary results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone deficient patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Growth hormone-deficient adults are insulin-resistant.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Low density lipoprotein particle size in hypopituitary adults receiving conventional hormone replacement therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Growth hormone (GH) and atherosclerosis: changes in morphology and function of major arteries during GH treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Endothelial dysfunction in hypopituitary adults with growth hormone deficiency.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Bone mineral status in growth hormone-deficient males with isolated and multiple pituitary deficiencies of childhood onset

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Consequences of childhood-onset growth hormone deficiency for adult bone mass

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Reduced bone mineral density in patients with adult onset growth hormone deficiency.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

7 January 2021

Growth hormone and bone

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Increased fracture frequency in adult patients with hypopituitarism and GH deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Skeletal muscle performance in adults with growth hormone deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Growth hormone treatment in growth hormone-deficient adults. II. Effects on exercise performance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Two years of growth hormone (GH) treatment increase isometric and isokinetic muscle strength in GH-deficient adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Left ventricular function in young adults with childhood and adulthood onset growth hormone deficiency.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Myocardial dysfunction in treated adult hypopituitarism: a possible explanation for increased cardiovascular mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Pitfalls in diagnosing impaired growth hormone (GH) secretion: retesting after replacement therapy of 63 patients defined as GH deficient.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Reevaluation of growth hormone (GH) secretion in 69 adults diagnosed as GH-deficient patients during childhood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Interpretative difficulties with growth hormone provocative retesting in childhood-onset growth hormone deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Growth Hormone (GH) Deficiency (GHD) of Childhood Onset: Reassessment of GH Status and Evaluation of the Predictive Criteria for Permanent GHD in Young Adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

The prevalence of severe growth hormone deficiency in adults who received growth hormone replacement in childhood [see comment]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Normal growth hormone secretion in growth hormone insufficient children retested after completion of linear growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Growth Hormone (GH) Provocative Retesting of 108 Young Adults with Childhood-Onset GH Deficiency and the Diagnostic Value of Insulin-Like Growth Factor I (IGF-I) and IGF-Binding Protein-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Growth hormone testing for the diagnosis of growth hormone deficiency in childhood: a population register-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

The severity of growth hormone deficiency in adults with pituitary disease is related to the degree of hypopituitarism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

The diagnosis of severe growth hormone deficiency in elderly patients with hypothalamic-pituitary disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

How (not) to diagnose growth hormone deficiency in adults: stimulated serum concentrations of growth hormone in healthy subjects and in patients with pituitary macroadenomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Elderly patients with adult-onset growth hormone deficiency are not osteopenic.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Diagnosis of growth hormone deficiency in adulthood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Is there a place for urinary growth hormone measurement?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

The use of growth hormone (GH) secretagogues in the diagnosis of GH deficiency in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Growth hormone dose regimens in adult GH deficiency: effects on biochemical growth markers and metabolic parameters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

The diagnosis of growth hormone deficiency in children and adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Clinical aspects of growth hormone deficiency in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Defining growth hormone deficiency in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Consensus Guidelines for the Diagnosis and Treatment of Adults with Growth Hormone Deficiency: Summary Statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

L-arginine and insulin-tolerance tests in the diagnosis of adult growth hormone deficiency: influence of confounding factors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Provocative tests of growth-hormone release. A comparison of results with seven stimuli.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Differential effects of arginine on growth hormone releasing hormone and insulin induced growth hormone secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

The assessment of growth hormone status in normal young adult males using a variety of provocative agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Diagnosis of growth-hormone deficiency in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Test of growth hormone secretion in adults: poor reproducibility of the insulin tolerance test

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

The Diagnosis of Growth Hormone Deficiency in Adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

An audit of the insulin tolerance test in adult subjects in an acute investigation unit over one year

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Serum growth hormone response to growth hormone-releasing hormone in non-obese and obese adults with hypopituitarism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

New approach to the diagnosis of growth hormone deficiency in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Hexarelin as a test of pituitary reserve in patients with pituitary disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Insulin-like growth factor-I in growth hormone-deficient adults: relationship to population-based normal values, body composition and insulin tolerance test.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Free Insulin-Like Growth Factor I Serum Levels in 1430 Healthy Children and Adults, and Its Diagnostic Value in Patients Suspected of Growth Hormone Deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Evaluation of free insulin-like growth factor-I measurement on the diagnosis and follow-up treatment of growth hormone-deficient adult patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Plasma IGF-I is a useful marker of growth hormone deficiency in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

A Specific Radioimmunoassay for the Growth Hormone (GH)-Dependent Somatomedin-Binding Protein: Its Use for Diagnosis of GH Deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Variables Controlling the Secretion of Insulin-Like Growth Factor Binding Protein-2 in Normal Human Subjects*

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Unanswered questions concerning the treatment of hyposomatotropism and hypogonadism in elderly men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Maximal secretory capacity of somatotrope cells in obesity: comparison with GH deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Pyridostigmine enhances, but does not normalise, the GH response to GH-releasing hormone in obese subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone secretion elicited by clonidine, arginine, or hypoglycemia in normal and obese subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Human growth hormone replacement therapy: pharmacological and clinical aspects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Individualized dose titration of growth hormone (GH) during GH replacement in hypopituitary adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Replacement treatment with biosynthetic human growth hormone in growth hormone-deficient hypopituitary adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Long-term cardiovascular effects of growth hormone treatment in GH-deficient adults. Preliminary data in a small group of patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Two years of replacement therapy in adults with growth hormone deficiency.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Effects of growth hormone replacement on physical performance and body composition in GH deficient adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

The optimal growth hormone replacement dose in adults, derived from bioimpedance analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Short and long-term effects of growth hormone treatment on bone turnover and bone mineral content in adult growth hormone-deficient males

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Effects of growth hormone (GH) replacement on bone metabolism and mineral density in adult onset of GH deficiency: results of a double-blind placebo-controlled study with open follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Long-term change in the bone mineral density of adults with adult onset growth hormone (GH) deficiency in response to short or long-term GH replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Effect of long-term growth-hormone substitution therapy on bone mineral density and parameters of bone metabolism in adult patients with growth hormone deficiency.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Effects of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Three years of growth hormone treatment in growth hormone-deficient adults: near normalization of body composition and physical performance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Growth hormone and the heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Cardiac performance: growth hormone enters the race

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Cardiovascular and renal effects of growth hormone.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Short and long-term cardiovascular effects of growth hormone therapy in growth hormone deficient adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Effects of growth hormone substitution on mental performance in adults with growth hormone deficiency: a pilot study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Quality of life in adults with growth hormone (GH) deficiency: response to treatment with recombinant human GH in a placebo-controlled 21-month trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Impact of recombinant human growth hormone treatment on psychological profiles in hypopituitary patients with adult-onset growth hormone deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Quality of life and cognitive function in patients with pituitary insufficiency.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Beneficial effects of long-term GH replacement therapy on quality of life in adults with GH deficiency.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Dose titration and patient selection increases the efficacy of GH replacement in severely GH deficient adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Whole-body leucine turnover in adults on conventional treatment for hypopituitarism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

The effects of growth hormone on protein metabolism in adult growth hormone deficient patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Effects of 1 year of growth hormone therapy on serum lipoprotein levels in growth hormone-deficient adults. Influence of gender and Apo(a) and ApoE phenotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

An open 36-month study of lipid changes with growth hormone in adults: lipid changes following replacement of growth hormone in adult acquired growth hormone deficiency.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Effects of four years' treatment with biosynthetic human growth hormone (GH) on glucose homeostasis, insulin secretion and lipid metabolism in GH-deficient adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Low dose recombinant human growth hormone normalizes bone metabolism and cortical bone density and improves trabecular bone density in growth hormone deficient adults without causing adverse effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Guidelines for optimizing growth hormone replacement therapy in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Gender difference in the response of growth hormone (GH)-deficient adults to GH therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men with low circulating IGF-I concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Growth hormone, insulin-like growth factor I, and benign intracranial hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

The safety profile of GH replacement therapy in adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Which adults develop side-effects of growth hormone replacement?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Changes in skeletal muscle and body composition after discontinuation of growth hormone treatment in growth hormone deficient young adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Discontinuation of growth hormone therapy in growth-hormone-deficient patients: assessment of body fat mass using bioelectrical impedance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

The effect of growth hormone replacement therapy for up to 12 months on lipoprotein composition and lipoprotein(a) in growth hormone-deficient adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose metabolism in adults with growth hormone deficiency.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Two weeks of daily injections and continuous infusion of recombinant human growth hormone (GH) in GH-deficient adults: I. Effects on insulin-like growth factor-I (IGF-I), GH and IGF binding proteins, and glucose homeostasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

A low individualized GH dose in young patients with childhood onset GH deficiency normalized serum IGF-I without significant deterioration in glucose tolerance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

The IGF axis in the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Circulating concentrations of insulin-like growth factor I and risk of breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Growth hormone and tumour recurrence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Is brain tumor recurrence increased following growth hormone treatment?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Adverse events during growth hormone therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0

Brain tumor recurrence in children treated with growth hormone: the National Cooperative Growth Study experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2800%2971334-0